Gabriela das Graças dos Santos Carolino

Gabriela das Graças dos Santos Carolino

Auto-generated profile, based on publicly available information

Gabriela das Graças dos Santos Carolino

Faculdade de Ciências Médicas e da Saúde de Juiz de Fora, Departamento de Medicina, Juiz de Fora MG, Brazil

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2026 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
LMLuana Miyahira Makita
Luana Miyahira Makita
GCGabriela das Graças dos Santos Carolino
Gabriela das Graças dos Santos Carolino
YSYuri Gubitose de Souza
Yuri Gubitose de Souza
HBHeloísa Carneiro Brito
Heloísa Carneiro Brito
MOMariana Oliveira
Mariana Oliveira
MPMario Fernando Prieto Peres
Mario Fernando Prieto Peres
Chronic migraine (CM) is often complicated by medication-overuse headache (MOH), worsening disability. Although withdrawal of overused medications is recommended, adherence is poor and relapse is frequent. Monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway may offer an effective preventive option without requiring discontinuation, but current evidence is limited by few and heterogeneous randomized controlled trials (RCTs). To systematically assess the efficacy and safety of anti-CGRP mAbs in treating CM with MOH (CM + MOH) under a conservative approach. The PubMed, Embase, and Cochrane Central databases were searched for RCTs comparing anti-CGRP mAbs with placebo in adults with CM + MOH. The primary outcome was the mean change in monthly migraine days (MMDs) at 3 months. The secondary outcomes included acute medication use, disability, drug overuse resolution, response rate, and adverse events (AEs). Random-effects models with Sidik-Jonkman estimator and Knapp-Hartung adjustments pooled effect sizes. We included seven RCTs, totalling 3,094 patients. Anti-CGRP mAbs significantly reduced MMDs (mean difference [MD] = -0.35; 95%CI: -0.43 to -0.26) and acute medication use (MD = -0.35; 95%CI: -0.51 to -0.19) compared with placebo. Higher rates, of ≥ 50%, of response (risk ratio [RR] = 1.94; 95%CI: 1.60–2.34) and drug overuse resolution (RR = 1.38; 95%CI: 1.04–1.83) were observed, with no significant increase in AEs (RR = 1.09; 95%CI: 0.85–1.40). Anti-CGRP mAbs were effective and well tolerated in CM + MOH, representing a viable alternative, especially for patients unable to discontinue acute medications. Further research should assess long-term outcomes and subgroup effects.